Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Torrent Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.
The historical rank and industry rank for Torrent Pharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:
NSE:TORNTPHARM'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 23.49 Med: 47.9 Max: 75.12
Current: 63.57
NSE:TORNTPHARM's Price-to-Owner-Earnings is ranked worse than 82.51% of 463
companies
in the Drug Manufacturers industry
Industry Median: 22.67
vs NSE:TORNTPHARM: 63.57
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by FactSet. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Torrent Pharmaceuticals Owner Earnings per Share (TTM) Related Terms
Torrent Pharmaceuticals Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for Torrent Pharmaceuticals's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Torrent Pharmaceuticals Owner Earnings per Share (TTM) Chart
NSE:TORNTPHARM vs ZTS: Owner Earnings per Share (TTM) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Torrent Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Torrent Pharmaceuticals Price-to-Owner-Earnings vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Torrent Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Torrent Pharmaceuticals's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
What does a Owner Earnings per Share (TTM) of 78.12 mean?
Torrent Pharmaceuticals (NSE:TORNTPHARM) has a Owner Earnings per Share (TTM) of 78.12 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Torrent Pharmaceuticals. According to the industry distribution chart, Torrent Pharmaceuticals ranks #382 out of 463 companies in the Drug Manufacturers industry, placing it in the top 82.5%.
Is Torrent Pharmaceuticals' Owner Earnings per Share (TTM) too high?
Torrent Pharmaceuticals' current Owner Earnings per Share (TTM) is 78.12. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 22.67. Torrent Pharmaceuticals' value of 78.12 is 244.6% above this industry median. Based on the distribution chart, Torrent Pharmaceuticals ranks #382 out of 463 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Torrent Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Torrent Pharmaceuticals' Owner Earnings per Share (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Torrent Pharmaceuticals ranks #382 out of 463 companies for Owner Earnings per Share (TTM). This places Torrent Pharmaceuticals in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 22.67. Torrent Pharmaceuticals' value of 78.12 is 244.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 22.67, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Torrent Pharmaceuticals's current Owner Earnings per Share (TTM) of 78.12 is 244.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Torrent Pharmaceuticals. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Torrent Pharmaceuticals's current Owner Earnings per Share (TTM) is 78.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Torrent Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Torrent Pharmaceuticals (NSE:TORNTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹4,987.14, compared to a current price of ₹4,840.00 — trading 3% below its estimated fair value. The current Owner Earnings per Share (TTM) is 78.12 and 244.6% above the Drug Manufacturers industry median of 22.67. Torrent Pharmaceuticals' overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Torrent Pharmaceuticals (NSE:TORNTPHARM), the current Owner Earnings per Share (TTM) is 78.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Torrent Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹4,840.00 is trading 3% below its estimated GF Value™ of ₹4,987.14.
GuruFocus considers Torrent Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:TORNTPHARM:
Owner Earnings per Share (TTM): 78.12
GF Value™: ₹4,987.14 vs. price of ₹4,840.00 (3% below fair value)
Industry Position: 244.6% above the Drug Manufacturers median (#382 of 463)
No single metric tells the full story. See the NSE:TORNTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
89GF Score
Get the complete analysis for NSE:TORNTPHARM
Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TORNTPHARM has been successfully added to your 
